Icon Advisers Inc. Co. continued to hold its position in shares of Humana Inc. (NYSE:HUM) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 4,400 shares of the insurance provider’s stock at the end of the 2nd quarter. Icon Advisers Inc. Co.’s holdings in Humana were worth $1,059,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Federated Investors Inc. PA boosted its stake in Humana by 608.1% in the 2nd quarter. Federated Investors Inc. PA now owns 34,626 shares of the insurance provider’s stock valued at $8,331,000 after purchasing an additional 29,736 shares during the period. Creative Planning boosted its stake in Humana by 0.3% in the 2nd quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock valued at $1,173,000 after purchasing an additional 15 shares during the period. Cipher Capital LP boosted its stake in Humana by 7.7% in the 2nd quarter. Cipher Capital LP now owns 9,734 shares of the insurance provider’s stock valued at $2,342,000 after purchasing an additional 698 shares during the period. OZ Management LP boosted its stake in Humana by 4.9% in the 2nd quarter. OZ Management LP now owns 667,478 shares of the insurance provider’s stock valued at $160,608,000 after purchasing an additional 30,927 shares during the period. Finally, US Bancorp DE boosted its stake in Humana by 4.4% in the 2nd quarter. US Bancorp DE now owns 44,359 shares of the insurance provider’s stock valued at $10,674,000 after purchasing an additional 1,870 shares during the period. Institutional investors and hedge funds own 95.14% of the company’s stock.

In related news, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the sale, the senior vice president now owns 14,258 shares of the company’s stock, valued at $3,421,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP M Todoroff Christopher sold 22,935 shares of Humana stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $252.52, for a total value of $5,791,546.20. Following the sale, the vice president now directly owns 24,001 shares of the company’s stock, valued at approximately $6,060,732.52. The disclosure for this sale can be found here. Insiders have sold 60,566 shares of company stock valued at $15,326,746 in the last three months. 0.80% of the stock is owned by corporate insiders.

Shares of Humana Inc. (NYSE:HUM) opened at 249.28 on Friday. The company has a market capitalization of $36.03 billion, a P/E ratio of 20.51 and a beta of 0.87. The company’s 50 day moving average price is $250.25 and its 200 day moving average price is $231.50. Humana Inc. has a 12 month low of $163.50 and a 12 month high of $259.76.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. The company had revenue of $13.53 billion during the quarter, compared to analyst estimates of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter last year, the company earned $2.30 earnings per share. Analysts expect that Humana Inc. will post $11.55 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Tuesday, August 29th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s dividend payout ratio is 13.06%.

Several analysts recently issued reports on HUM shares. Zacks Investment Research downgraded Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Leerink Swann boosted their price target on Humana from $250.00 to $265.00 and gave the company an “outperform” rating in a research note on Tuesday, May 30th. Royal Bank Of Canada restated a “hold” rating and issued a $214.00 price target on shares of Humana in a research note on Monday, June 5th. Morgan Stanley started coverage on Humana in a research note on Tuesday, June 6th. They issued an “overweight” rating and a $262.00 price target for the company. Finally, Argus upgraded Humana from a “hold” rating to a “buy” rating and set a $260.00 price target for the company in a research note on Friday, June 9th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $244.35.

COPYRIGHT VIOLATION NOTICE: “Icon Advisers Inc. Co. Has $1,059,000 Stake in Humana Inc. (HUM)” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/09/17/icon-advisers-inc-co-has-1059000-stake-in-humana-inc-hum.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.